GlassScriptPhysician profile
Kevin S Weibel
NPI 1104864016
$4,936.18
in general payments reported to CMS, 2019-2025
50 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $346 · 2021: $235 · 2022: $704 · 2023: $1,197 · 2024: $1,019 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Long Term Medical Supply Or Device Loan: $1,446 · Education: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.40 |
| Long Term Medical Supply Or Device Loan | $1,446.39 |
| Education | $447.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,660.33 | 2022-2025 | |
| Pfizer INC. | $631.86 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $329.90 | 2019-2024 | Imfinzi, Enhertu |
| Astellas Pharma US INC | $186.54 | 2020-2025 | Vyloy |
| Daiichi Sankyo INC. | $161.97 | 2021-2024 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $138.16 | 2019-2024 | Opdivo |
| Celgene Corporation | $119.03 | 2019-2023 | Pomalyst |
| Aveo Pharmaceuticals, INC. | $118.96 | 2023 | Fotivda |
| Genentech USA, INC. | $110.97 | 2020-2024 | Polivy, Lunsumio, Columvi |
| Seagen INC. | $102.74 | 2020-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $91.79 | 2019-2024 | Keytruda |
| Ipsen Biopharmaceuticals, INC | $81.15 | 2024 | Onivyde, Tazverik |
| Janssen Biotech, INC. | $73.45 | 2022-2023 | Tecvayli, Darzalex |
| Array Biopharma INC | $72.59 | 2019-2023 | Mektovi, Lorbrena, Braftovi |
| Exelixis INC. | $69.99 | 2023 |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Weibel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.